BLU-945 |
| Catalog No.GC63910 |
BLU-945 es un inhibidor de la tirosina quinasa (TKI) del receptor del factor de crecimiento epidérmico (EGFR) potente, altamente selectivo, reversible y activo por vÍa oral. BLU-945 puede inhibir eficazmente EGFR con mutaciÓn de deleciÓn L858R y/o exÓn 19, mutaciÓn T790M y mutaciÓn C797S. BLU-945 se puede utilizar para la investigaciÓn del cÁncer de pulmÓn, incluido el cÁncer de pulmÓn de células no pequeÑas (NSCLC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2660250-10-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
receptor (EGFR). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112)[1].
[1]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *